# 1st Gen Model McKesson Corporation Drugs, proprietaries, & sundries

70.13% successful of 77 deals
$162.60 Last close price
at 15-dec-2017


Model's trade recommendations 0.76% Return for period

-3.15% Annual return

$32.36B Market Cap

β 1.23  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 0.76%
52wk return 20.35%
52wk Range
Sortino ratio -0.17
Sharpe ratio -0.14
Norm. RMSE 0.43%
Downside risk 13.31%
Volatility 15.77%
  • 1.36 (0.88%) Div (Yield)
  • BUY Analysts consensus recommendation

McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by their ICARE shared principles, their employees work every day to innovate and deliver opportunities that make their customers and partners more successful - all for the better health of patients. McKesson has been named the `Most Admired Company` in the healthcare wholesaler category by FORTUNE, a `Best Place to Work` by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly.

Industry sector: Medical

Sector classification: Drugs, proprietaries, & sundries

Deep Learning based analysis and prediction model for McKesson Corporation (MCK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MCK model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 206M
P/E 12.76
Shares Outstanding 208M
% Held by Insiders 1.20%
% Held by Institutions 88.10%
EPS (last reported FY) $11.61
EPS (last reported Q) $3.28
EPS, estimated (last reported Q) $2.78
Total revenues $199 B
Net income $5 B